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Background: Cancer cells are characterized by a deregulated cell cycle that facilitates abnormal proliferation by
allowing cells to by-pass tightly regulated molecular checkpoints such as the G1/S restriction point. To facilitate
early diagnosis and the identification of new drug targets, current research efforts focus on studies that could lead
to the development of protein panels that collectively can improve the effectiveness of our response to the
detection of a life-threatening disease.
Methods: Estrogen-responsive MCF-7 cells were cultured and arrested by serum deprivation in the G1-stage of the
cell cycle, and fractionated into nuclear and cytoplasmic fractions. The protein extracts were trypsinized and
analyzed by liquid chromatography - mass spectrometry (MS), and the data were interpreted with the Thermo
Electron Bioworks software. Biological characterization of the data, selection of cancer markers, and identification of
protein interaction networks was accomplished with a combination of bioinformatics tools provided by GoMiner,
DAVID and STRING.
Results: The objective of this work was to explore via MS proteomic profiling technologies and bioinformatics data
mining whether randomly identified cancer markers can be associated with the G1-stage of the cell cycle, i.e., the
stage in which cancer cells differ most from normal cells, and whether any functional networks can be identified
between these markers and placed in the broader context of cell regulatory pathways. The study enabled the
identification of over 2000 proteins and 153 cancer markers, and revealed for the first time that the G1-stage of the
cell cycle is not only a rich source of cancer markers, but also a host to an intricate network of functional
relationships within the majority of these markers. Three major clusters of interacting proteins emerged:
(a) signaling, (b) DNA repair, and (c) oxidative phosphorylation.
Conclusions: The identification of cancer marker regulatory components that act not alone, but within networks,
represents an invaluable resource for elucidating the moxlecular mechanisms that govern the uncontrolled
proliferation of cancer cells, as well as for catalyzing the development of protein panels with biomarker and drug
target potential, screening tests with improved sensitivity and specificity, and novel cancer therapies aimed at
pursuing multiple drug targets.
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Howard and Pelc described four consecutive phases of
the cell cycle: G1, S, G2 and M [1]. Each phase needs to
be completed before the next one can proceed: the G1-
phase is a period of growth in preparation for replica-
tion, the S-phase a period in which the DNA content is
duplicated, the G2-phase a period of growth in prepar-
ation for mitosis, and the M-phase a period in which the
cell divides into two identical daughter cells. Multiple
regulatory events, termed checkpoints, verify whether
certain cellular processes have occurred properly before
allowing the cells to proceed from one phase to another
[2-6]. For example, DNA damage checkpoints at the G1/
S and G2/M transition boundaries, and spindle check-
points during the M-phase, have been recognized. These
checkpoints allow either for DNA repair, or correct
chromosome alignment on the mitotic spindle, respect-
ively, before the next steps of the cell cycle can proceed.
In 1978, Pardee described the G1/S restriction point
(R-point) as an essential regulatory event in the G1-
phase [3]. The period before the R-point is uniquely sen-
sitive to growth factor stimulation, and in the absence of
mitogenic signaling, normal cells exit the cell cycle and
enter a reversible dormant/quiescent state termed G0.
Alternatively, in the presence of major perturbations in
the cell cycle regulatory machinery, such as DNA dam-
age, normal cells attempt to repair such damage, or in
the case of failure, commit apoptosis. Unlike normal
cells, cancer cells evolved the ability to evade the restric-
tion point and continue through the cell cycle even if
DNA damage is detected. After the R-point, both normal
and cancer cells are unaffected by the removal of growth
factors or other deregulatory events, and enter the S-
phase, committing to a round of cell division. Therefore,
the R-point emerges as the most critical point in cell
cycle control. Key to its regulation is the phosphoryl-
ation of the retinoblastoma protein (pRb or RB1) by ac-
tive cyclin D-CDK4/6 and cyclin E-CDK2 complexes in
early and late G1, respectively, an event that results in
the release of E2F transcription factors that signal the
cell to continue into the S-phase, replicate and prolifer-
ate. Hundreds of E2F target genes that are involved in
DNA replication and cell cycle signaling, as well as DNA
damage repair, programmed cell death, development and
cell differentiation, have been identified. Traditional mo-
lecular biology and biochemistry approaches have greatly
contributed to understanding breast cancer cell cycle
regulation. However, the introduction of high-throughput
genomic and proteomic methods, and the escalating de-
velopment of novel bioinformatics tools, have revolution-
ized cancer research. Large lists of genes and proteins
involved in important biological processes are generated
with the aim of providing a comprehensive picture of all
concurring events in a cell, the challenge continuing torest with the interpretation of such voluminous data. As
the mechanisms used by cancer cells to escape the R-
restriction point continue to remain unclear, the objective
of this study was to use mass spectrometry technologies
to generate a comprehensive map of proteins that are
expressed in the critical G1-stage of the cell cycle in a rep-
resentative model system of ER + breast cancer such as
MCF-7, and make use of bioinformatics tools to explore:
(a) whether cancer marker proteins reported by previous
studies (rather unrelated) can be associated with this stage
of the cell cycle, (b) whether a particular subcellular
localization is characteristic for these proteins, and (c)
whether these markers form regulatory networks that pro-
mote cell proliferation and can be placed in a broader con-
text of cancer-relevant functional roles to advance a panel
with biomarker and drug target potential.
Methods
Cell processing
MCF-7 cells (ATCC, Manassas, VA) were grown in
EMEM with 10% FBS and 10 μg/mL bovine insulin, in
an incubator at 37°C with 5% CO2 [7,8]. The cells were
arrested in the G1-phase by serum-deprivation for 48 h,
in a medium consisting of DMEM and 4 mM L-glutam-
ine, harvested, separated into nuclear and cytoplasmic
fractions (Cell Lytic™ NuCLEAR™ extraction kit, Sigma, St.
Louis, MO), digested with trypsin (Promega Corporation
(Madison, WI) at 37°C for 24 h (50:1 substrate:enzyme
ratio), and analyzed by nano-liquid chromatography (LC)-
MS/MS with a linear trap quadrupole (LTQ/Thermo Elec-
tron Corporation, San Jose, CA) mass spectrometer. FACS
analysis was performed with a Beckman Coulter EPICS
XL-MCL analyzer (Brea, CA, USA). The protein content
was measured by the Bradford assay on a SmartSpec Plus
spectrophotometer (Bio-Rad, Hercules, CA). The sample
analyzed by MS contained 2 μg/μL MCF-7 proteins. LC
separations were performed with an Agilent 1100 LC sys-
tem (Palo Alto, CA) and in-house prepared nano-
separation columns (100 μm i.d. x 12 cm) packed with
5 μm Zorbax SB-C18 particles. Common reagents were
purchased from Sigma, cell culture media from ATCC
and Invitrogen (Carlsbad, CA), and HPLC-solvents from
Fisher Scientific (Fair Lawn, NJ). Sample preparation and
LC-MS/MS analysis protocols were described in detail in
previous manuscripts [7,8].
Data processing
A minimally redundant Homo sapiens protein database
from SwissProt (2008/40,009 entries) and the Bioworks
3.3 software (Thermo Electron) were used for protein
identifications. Conditions for peptide selection in-
cluded: only fully tryptic fragments with maximum two
missed cleavages, no posttranslational modifications,
peptide and fragment ion tolerances set at 2 amu and
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any combination of theoretical b, y and a ions), all pep-
tides matched to unique proteins in the database, and
Sequest Xcorr vs. charge state parameters set at 1.9, 2.2
and 3.8 for singly, doubly and triply charged peptides,
respectively. At the protein level, the Bioworks p-score
threshold was set at ≤0.001. Proteins matched by one
unique peptide were considered only when could be
identified in at least two biological states or replicates. A
few proteins matched by a single peptide count were
allowed in the analysis, due to their relevance, but the
associated SwissProt IDs should be treated in such cases
with prudence due to the possibility of existing protein
isoforms that share the same peptide. The peptide p-
values were for these cases < 0.001. False discovery rates
(FDR) were determined by searching the raw data
against a forward-reversed protein sequence database.
FDRs were <3% and <1% at the protein and peptide
levels, respectively. Specific parameter settings for the
use of bioinformatics tools were: GoMiner included all
evidence codes; STRING parameters were set to high
confidence, ≤10 interactors, network depth 1 and all ac-
tive prediction methods; the DAVID enrichment p-score
threshold was 1.3 (shown as -log transformed value),
with a Homo sapiens background and classification strin-
gency set to medium.
Results and discussion
Sample and data analysis
While the key events of the cell cycle control take place
in the nucleus, a number of relevant signaling pathways
activated by mitogenic stimuli proceed through the cyto-
plasm, prior to impacting the nuclear sequence of events.
Furthermore, many proteins are shuttled between the cyto-
plasm and nucleus as a means of functional activation/Figure 1 FACS analysis of MCF-7 cells. (A) Bar graph illustrating the repr
in three biological replicate cultures; (B) FACS diagram of G1-stage MCF-7deactivation. To increase the number of identifiable pro-
teins and generate a comprehensive map of the biological
processes that unfold in the G1-stage of the cell cycle, the
MCF-7 cells were separated into nuclear and cytoplasmic
fractions. Three biological replicates were prepared to
enable a confident selection of identifiable proteins, and
five LC-MS/MS technical replicates were performed to
maximize the number of identifiable proteins and the
number of spectral counts per protein [7,8]. A total of six
samples were generated from the two cell states [i.e., G1-
phase nuclear (G1N1, G1N2 and G1N3) and G1-phase
cytoplasmic (G1C1, G1C2 and G1C3)] and a total of 30
LC-MS/MS analyses were performed. Reproducibility was
assessed at every step of the analysis. The cell cycle distri-
bution in each cell culture was evaluated by flow cytometry
(Figure 1). The arrested cells were found primarily in G1
(~81%), and only a small proportion in S (~10%) and G2
(~7%), respectively. A bar graph illustrating the trend in
protein identifications is provided in Figure 2. Each bio-
logical replicate displays cumulative protein identifications
in 5 LC-MS/MS analyses, and new protein identifications
relative to the previous replicates. After MS data process-
ing and filtering, in-house developed Perl-scripts were used
for aligning protein and peptide spectral count data [9]. A
total of 2375 proteins were identified, of which, 2000 with
two or more spectral counts. The average number of iden-
tified proteins and matching counts in each of the 6 cell
states was 1176 (CV = 7.5%) and 4030 (CV = 8.9%), re-
spectively, with a total of 1515 proteins in the combined
nuclear fractions and 1572 in the combined cytoplasmic
fractions. The correlation coefficient of protein identifica-
tions based on spectral count data in any two biological
replicates of a cell state reached values as high as R = 0.96,
as shown in a representative comparison involving the












Biological states and replicates
Figure 2 Reproducibility of protein identifications in three biological replicates of G1N/G1C MCF-7 cells.
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logical and technical variability, the effective overlap of pro-
tein IDs between all three replicates did not exceed ~75%
(Figure 3B). Nevertheless, the above described workflow en-
abled the identification of a sufficient number of proteins
for extracting meaningful biological information despite the
lack of a high-end mass spectrometer platform for perform-
ing the experiments. The ExPASy Proteomics Server [10],
GoMiner [11], DAVID Bioinformatics Resources [12,13],
STRING functional protein association networks 8.3 [14]
and the GeneCards [15] bioinformatics tools were used for
the functional interpretation of the data. GoMiner analysis
revealed that the nuclear cell fractions comprised 57–62%
and 59–64% proteins with nuclear and cytoplasmic
categorization, respectively. The cytoplasmic fractions
comprised primarily cytoplasmic proteins (83–84%), and
only a small fraction of nuclear proteins (32–33%). While
complete separation of the two cell fractions was not ex-
perimentally achievable, the nuclear enrichment process re-
sulted in an increase of the nuclear proteins from 15–20%
in a whole cell extract, to >50% in the nuclear-enrichedA
Figure 3 Protein overlaps among biological replicates of MCF-7 cells.
MCF-7 G1N cells (G1N1 vs. G1N2, total 1239 proteins). (B) Venn diagram of prfraction. DAVID functional clustering of the MCF-7 pro-
teins with two or more spectral counts returned over 150
clusters with enrichment scores > 1.3. The large number of
clusters reflects that the dataset is representative of a broad
range of basic biological processes that occur in a cell. The
top scoring clusters included processes related to the bio-
synthesis and processing of nucleotides, RNA, proteins and
ATP, and to transport, proteasome and metabolism.
Additional file 1 lists the identified proteins, their total
spectral count, and their identification in the nuclear or
cytoplasmic fractions. The overlapping nuclear/cytoplasmic
categories (i.e., ~30%) included proteins with roles in gene
expression/translation/protein biosynthesis, glycolysis, glu-
cose/carbohydrate metabolism, and intracellular transport.
Query for putative cancer markers
Overall, from the list of 2375 proteins, GoMiner/DAVID
categorization returned a considerable number of pro-
teins involved in biological processes representative of
all hallmarks of cancer [6,16] that matched multiple
pathways in the Kegg cancer diagram, i.e., proliferation,B
(A) Scatter plot of protein identifications in two biological replicates of
otein overlaps between three biological replicates of MCF-7 G1N cells.
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genes, insensitivity to growth factors, sustained angio-
genesis, and PPAR signaling [17]. The list of 2375 was
queried for the presence of proteins with role in cancer
development or with previously reported biomarker po-
tential. The search in the DAVID disease database
returned a list of 96 proteins associated with cancer, of
which 51 proteins were matched to breast cancer. Table 1
enlists the identified markers and spectral count data,
categorized according to biological processes of rele-
vance to cancer. Additional file 2 enlists supplemental
information such as associated GO biological processes,
GO cellular compartments, GO molecular functions,
Kegg pathways and associated diseases, STRING de-
scriptions, full Sequest report and gene abbreviations.
Table 1 was complemented with a set of 57 G1-stage
proteins with known significance to cell cycle regulation
and cancer [6,12,15], shown as entries in italic, to
amount to a total of 153 protein I.D.s.
Proteins of relevance to cancer, but not identified in
the dataset, were included in the discussion, but were
not included in the generation of lists, figures or the
STRING diagrams. Cancer-relevant proteins were
present in both nuclear (100 proteins) and cytoplasmic
(102 proteins) fractions. Most importantly, a STRING
protein-protein interaction diagram revealed a wide-
spread connectivity between these randomly mapped
cancer proteins, and redundant identification of the
same categories with relevance to cell cycle regulation
and proliferation, suggesting the possibility of a useful
biomarker panel for diagnostic purposes, or of novel
drug candidates that could be targeted synergistically in
cancer therapy (Figure 4). Three main networks emerged
from the list: (1) signaling and cell cycle regulation, (2)
maintenance of genome integrity and DNA repair, and
(3) oxidative phosphorylation, stress, energy production
and metabolism. While the advocated protein panel is
not necessarily specific to MCF-7, and while differential
expression profiling was not the purpose of the present
study, preliminary comparisons to non-tumorigenic G1-
arrested MCF-10 cells confirmed that roughly two thirds
of the MCF-7 markers changed spectral counts more
than 2-fold, and some even more than 10-fold, when
comparted to MCF-10. The results also confirm that
proteomic analysis of relevant cancerous cell states can
capture in a single experiment protein panels that previ-
ously could be identified only by multiple studies, with
various model systems, and using various biochemical/
biological approaches and tools. A subset of proteins dis-
played either very small, or, essentially, no change in
spectral counts (APEX1, KU70/KU86, LEG3, PARP1,
PGK1, PHB, PRDX2, PRKDC, RAC1, RHOA/RHOC,
SHC1, TBB3/TBB5, TYB4, UCRI, ZO). Future work will
discuss in detail the quantitative comparison of the twocell lines in both nuclear and cytoplasmic fractions. The
functional relevance of the most prominent protein
clusters that were identified within the three major
categories, as well as their broader impact on cancer cell
proliferation is discussed below.
Cell cycle regulation, proliferation and checkpoint
Among the key cell cycle and proliferation regulators,
the cell cycle and mitotic checkpoint proteins with es-
sential roles in maintaining the integrity of the cell div-
ision process (PRKDC, TP53BP1, BUB3, RB1), the
proliferation markers (PCNA, KI-67, 14-3-3 sigma,
PHB), the cyclin dependent kinases CDK2 and CDK1
(CDC2), the alpha and beta catalytic subunits of the pro-
tein phosphatase type 1 PP1 (PP1A and PP1B), and a
series of other proteins that control transcription regula-
tion, chromatin maintenance, mitosis, signaling and prote-
asome degradation, were identified. The phosphorylation
of the RB1 protein by cyclin D1-CDK4/6 complexes plays
an important role in cell advancement through the cell
cycle and the regulation of the R-point: the unphosphory-
lated form is present in G0, hypophosphorylation corre-
lates to entry into G1, and hyperphosphorylation is
concurrent with passing of the restriction point and com-
pletion of the cell cycle. Upon exit from mitosis, the phos-
phate groups are removed by the Ser/Thr-protein
phosphatase PP1 proteins [6]. Along with the cyclin-CDK
complexes, protein phosphatases play an important role in
cell cycle control through their modulation of signal trans-
duction pathways. Active CDK2 is essential after the R-
point, in late G1 and S, one of its roles in S being the
phosphorylation of pol-α:primase which promotes DNA
synthesis in S. Active CDK1 is essential in the M-phase,
and also for entry into the S-phase in the absence of
CDK2 [18]. Along with RB1, the guardian of the R-point
gate, BUB3 acts as an M-phase mitotic spindle assembly
checkpoint protein and inhibitor of the anaphase promot-
ing complex (APC) that tags cell cycle proteins with ubi-
quitin for proteasomal degradation by the 26S proteasome
[15]. TP53BP, through its association with p53, plays a key
role in DNA damage response and transcription regula-
tion, and PRKDC, a Ser/Thr kinase, in association with
XRCC5/6 is a first-line responder and sensor of DNA
damage. In parallel with their essential function in DNA
repair, these proteins have additional roles in cell cycle
regulation [12-15].
Consistent with cancer cell propagation, a number of
known proliferation markers were detectable, i.e., PCNA,
antigen Ki-67, 14-3-3 sigma and prohibitin-PHB [15,19].
PCNA is involved in the control of eukaryotic DNA repli-
cation, and displays high expression levels in proliferating
cells. Ki-67 is a marker of proliferation, being detectable in
all stages of the cell cycle, except G0. 14-3-3 sigma is an
adaptor protein which is involved in multiple signaling
Table 1 Biological categorization of MCF-7 proteins matched in the DAVID disease/cancer database (entries in italic are
not all cancer markers, but were included in the list due to their functional relevance to the marker proteins)
ID Protein name MW Total counts Cancer Breast cancer
Cell cycle/division/check-point/proliferation
O43684 BUB3_HUMAN Mitotic checkpoint protein BUB3 37131.2 78 Cancer Breast cancer
P06400 RB_HUMAN Retinoblastoma-associated protein 106091.7 15 Cancer Breast cancer
P12004 PCNA_HUMAN Proliferating cell nuclear antigen 28750.3 17 Cancer
P35232 PHB_HUMAN Prohibitin 29785.9 96 Cancer Breast cancer
P78527 PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit 468786.9 889 Cancer Breast cancer
P07437 TBB5_HUMAN Tubulin beta chain 49639 230 Cancer Breast cancer
Q13509 TBB3_HUMAN Tubulin beta-3 chain 50400.3 127 Cancer Breast cancer
Q14980 NUMA1_HUMAN Nuclear mitotic apparatus protein 1 238113.2 505 Cancer Breast cancer
Q12888 TP53B_HUMAN Tumor suppressor p53-binding protein 1 213440.8 7 Cancer Breast cancer
Q6P1J9 CDC73_HUMAN Parafibromin 60539.2 12 Cancer
P37231 PPARG_HUMAN Peroxisome proliferator-activated receptor gamma 57583.2 5 Cancer Breast cancer
P46013 KI67_HUMAN Antigen KI-67 358471.9 50
P31947 1433S_HUMAN 14-3-3 protein sigma 27756.7 67
Q8IX12 CCAR1_HUMAN Cell division cycle and apoptosis regulator protein 1 132738.6 72
P06493 CDC2_HUMAN Cell division control protein 2 homolog 34073.9 20
P62136 PP1A_HUMAN Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 37487.8 179
P62140 PP1B_HUMAN Serine/threonine-protein phosphatase PP1-beta catalytic subunit 37162.6 9
Q13616 CUL1_HUMAN Cullin-1 89622 12
Q13547 HDAC1_HUMAN Histone deacetylase 1 55067.8 120
Q92769 HDAC2_HUMAN Histone deacetylase 2 55328.8 31
Apoptosis
O14737 PDCD5_HUMAN Programmed cell death protein 5 14276.3 6 Cancer
Q07812 BAX_HUMAN Apoptosis regulator BAX 21170.8 1 Cancer
Q13153 PAK1_HUMAN Serine/threonine-protein kinase PAK 1 60608.8 4 Cancer
O43464 HTRA2_HUMAN Serine protease HTRA2, mitochondrial precursor 48811 5
O75340 PDCD6_HUMAN Programmed cell death protein 6 21854.8 103
O95831 AIFM1_HUMAN Apoptosis-inducing factor 1, mitochondrial precursor 66859 57
P55957 BID_HUMAN BH3-interacting domain death agonist 21981.1 7
Q13158 FADD_HUMAN Protein FADD 23264.9 10
Q8IX12 CCAR1_HUMAN Cell division cycle and apoptosis regulator protein 1 132738.6 72
Q8N8D1 PDCD7_HUMAN Programmed cell death protein 7 54666.3 4
Q96IZ0 PAWR_HUMAN PRKC apoptosis WT1 regulator protein 36545.5 5
Q9BTC0 DIDO1_HUMAN Death-inducer obliterator 1 243720.8 76
Q9BZZ5 API5_HUMAN Apoptosis inhibitor 5 57525.2 75
Q9NR28 DBLOH_HUMAN Diablo homolog, mitochondrial precursor 27113.7 8
Q9NYF8 BCLF1_HUMAN Bcl-2-associated transcription factor 1 106058.7 80
Q9ULZ3 ASC_HUMAN Apoptosis-associated speck-like protein containing a CARD 21613.3 43
DNA Repair
O00255 MEN1_HUMAN Menin 67951 4 Cancer
P09874 PARP1_HUMAN Poly [ADP-ribose] polymerase 1 113012.4 342 Cancer Breast cancer
P12004 PCNA_HUMAN Proliferating cell nuclear antigen 28750.3 17 Cancer
P12956 KU70_HUMAN ATP-dependent DNA helicase 2 subunit 1 69799.2 398 Cancer Breast cancer
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Table 1 Biological categorization of MCF-7 proteins matched in the DAVID disease/cancer database (entries in italic are
not all cancer markers, but were included in the list due to their functional relevance to the marker proteins)
(Continued)
P13010 KU86_HUMAN ATP-dependent DNA helicase 2 subunit 2 82652.4 367 Cancer Breast cancer
P16455 MGMT_HUMAN Methylated-DNA--protein-cysteine methyltransferase 21632.2 22 Cancer Breast cancer
P18074 ERCC2_HUMAN TFIIH basal transcription factor complex helicase subunit 86854.3 3 Cancer Breast cancer
P18887 XRCC1_HUMAN DNA-repair protein XRCC1 69483.1 15 Cancer Breast cancer
P20585 MSH3_HUMAN DNA mismatch repair protein Msh3 127376.1 5 Cancer
P27695 APEX1_HUMAN DNA-(apurinic or apyrimidinic site) lyase 35532.2 78 Cancer Breast cancer
P29372 3MG_HUMAN DNA-3-methyladenine glycosylase 32842.8 36 Cancer
P35244 RFA3_HUMAN Replication protein A 14 kDa subunit 13559.9 29 Cancer
P43246 MSH2_HUMAN DNA mismatch repair protein Msh2 104676.8 21 Cancer
P46063 RECQ1_HUMAN ATP-dependent DNA helicase Q1 73409.1 10 Cancer
P49916 DNL3_HUMAN DNA ligase 3 102625.5 4 Cancer Breast cancer
P52701 MSH6_HUMAN DNA mismatch repair protein MSH6 152688.4 37 Cancer
P54727 RD23B_HUMAN UV excision repair protein RAD23 homolog B 43144.6 78 Cancer Breast cancer
P78527 PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit 468786.9 889 Cancer Breast cancer
Q01831 XPC_HUMAN DNA-repair protein complementing XP-C cells 105915.3 14 Cancer Breast cancer
Q12888 TP53B_HUMAN Tumor suppressor p53-binding protein 1 213440.8 7 Cancer Breast cancer
Q92466 DDB2_HUMAN DNA damage-binding protein 2 47833.4 5 Cancer
Q92878 RAD50_HUMAN DNA repair protein RAD50 153795.8 11 Cancer Breast cancer
Q9UBB5 MBD2_HUMAN Methyl-CpG-binding domain protein 2 43228 7 Cancer Breast cancer
Q9UHN1 DPOG2_HUMAN DNA polymerase subunit gamma-2, mitochondrial precursor 54876.3 7 Cancer
P39748 FEN1_HUMAN Flap endonuclease 1 42566.1 114
Angiogenesis
P13489 RINI_HUMAN Ribonuclease inhibitor 49941.2 17 Cancer
P40763 STAT3_HUMAN Signal transducer and activator of transcription 3 88011.4 13 Cancer
Q16539 MK14_HUMAN Mitogen-activated protein kinase 14 41267.1 2
Q14119 VEZF1_HUMAN Vascular endothelial zinc finger 1 56326.5 9
Q13685 AAMP_HUMAN Angio-associated migratory cell protein 46721.5 1
Q9UQB8 BAIP2_HUMAN Brain-specific angiogenesis inhibitor 1-associated protein 60829.7 5
Q92793 CBP_HUMAN CREB-binding protein 265180.1 2
Migration/invasion/adhesion/metastasis
P07858 CATB_HUMAN Cathepsin B precursor 37796.8 6 Cancer
P15941 MUC1_HUMAN Mucin-1 precursor 121999.6 4 Cancer
P17931 LEG3_HUMAN Galectin-3 26172.1 77 Cancer
P35222 CTNB1_HUMAN Catenin beta-1 85442.3 1 Cancer
P62328 TYB4_HUMAN Thymosin beta-4 5049.5 15 Cancer
Q06124 PTN11_HUMAN Tyrosine-protein phosphatase non-receptor type 11 68393.4 2 Cancer
Q08380 LG3BP_HUMAN Galectin-3-binding protein precursor 65289.4 2 Cancer
Q13153 PAK1_HUMAN Serine/threonine-protein kinase PAK 1 60608.8 4 Cancer
Q13330 MTA1_HUMAN Metastasis-associated protein MTA1 80737.4 13 Cancer Breast cancer
O60716 CTND1_HUMAN Catenin delta-1 108103.3 37
P07339 CATD_HUMAN Cathepsin D precursor 44523.7 105
P07355 ANXA2_HUMAN Annexin A2 38579.8 627
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Table 1 Biological categorization of MCF-7 proteins matched in the DAVID disease/cancer database (entries in italic are
not all cancer markers, but were included in the list due to their functional relevance to the marker proteins)
(Continued)
P09493 TPM1_HUMAN Tropomyosin alpha-1 chain 32688.7 91
P12814 ACTN1_HUMAN Alpha-actinin-1 102992.7 441
P23528 COF1_HUMAN Cofilin-1 18490.7 508
P35221 CTNA1_HUMAN Catenin alpha-1 100008.6 100
P35580 MYH10_HUMAN Myosin-10 228796.8 136
P60953 CDC42_HUMAN Cell division control protein 42 homolog precursor 21296.9 3
P61586 RHOA_HUMAN Transforming protein RhoA precursor 21754.1 12
P62258 1433E_HUMAN 14-3-3 protein epsilon 29155.4 136
P63000 RAC1_HUMAN Ras-related C3 botulinum toxin substrate 1 precursor 21436.3 9
Q07157 ZO1_HUMAN Tight junction protein ZO-1 195338.8 32
Q13418 ILK_HUMAN Integrin-linked protein kinase 51386 43
Q9UDY2 ZO2_HUMAN Tight junction protein ZO-2 133890.2 5
Q13685 AAMP_HUMAN Angio-associated migratory cell protein 46721.5 1
P08134 RHOC_HUMAN Rho-related GTP-binding protein RhoC precursor 21992.3 4
Differentiation
P15531 NDKA_HUMAN Nucleoside diphosphate kinase A 17137.7 154 Cancer Breast cancer
P33076 C2TA_HUMAN MHC class II transactivator 123379.3 2 Cancer
O60869 EDF1_HUMAN Endothelial differentiation-related factor 1 16358.9 9
O95758 ROD1_HUMAN Regulator of differentiation 1 56466.5 15
P09382 LEG1_HUMAN Galectin-1 14706.2 7
P17931 LEG3_HUMAN Galectin-3 26172.1 77 Cancer
P23771 GATA3_HUMAN Trans-acting T-cell-specific transcription factor GATA3 47885.3 3
P35221 CTNA1_HUMAN Catenin alpha-1 100008.6 100
P37231 PPARG_HUMAN Peroxisome proliferator-activated receptor gamma 57583.2 5 Cancer Breast cancer
P40763 STAT3_HUMAN Signal transducer and activator of transcription 3 88011.4 13 Cancer
Q8TB36 GDAP1_HUMAN Ganglioside-induced differentiation-associated protein 1 41225.8 2
Signaling
O00170 AIP_HUMAN AH receptor-interacting protein 37640.2 18 Cancer Breast cancer
O14908 GIPC1_HUMAN PDZ domain-containing protein GIPC1 36026.7 34 Cancer Breast cancer
P01112 RASH_HUMAN GTPase HRas precursor 21284.6 6 Cancer Breast cancer
P02786 TFR1_HUMAN Transferrin receptor protein 1 84818 19 Cancer Breast cancer
P08107 HSP71_HUMAN Heat shock 70 kDa protein 1 70009.2 560 Cancer
P11142 HSP7C_HUMAN Heat shock cognate 71 kDa protein 70854.4 895 Cancer
P15941 MUC1_HUMAN Mucin-1 precursor 121999.6 4 Cancer
P16615 AT2A2_HUMAN Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 114682.7 8 Cancer
P29353 SHC1_HUMAN SHC-transforming protein 1 62812.6 8 Cancer Breast cancer
P33076 C2TA_HUMAN MHC class II transactivator 123379.3 2 Cancer
P34931 HS71L_HUMAN Heat shock 70 kDa protein 1 L 70331.5 482 Cancer
P35222 CTNB1_HUMAN Catenin beta-1 85442.3 1 Cancer
P37231 PPARG_HUMAN Peroxisome proliferator-activated receptor gamma 57583.2 5 Cancer Breast cancer
P40763 STAT3_HUMAN Signal transducer and activator of transcription 3 88011.4 13 Cancer
P78527 PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit 468786.9 889 Cancer Breast cancer
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Table 1 Biological categorization of MCF-7 proteins matched in the DAVID disease/cancer database (entries in italic are
not all cancer markers, but were included in the list due to their functional relevance to the marker proteins)
(Continued)
Q04206 TF65_HUMAN Transcription factor p65 60181.6 2 Cancer
Q06124 PTN11_HUMAN Tyrosine-protein phosphatase non-receptor type 11 68393.4 2 Cancer
Q07812 BAX_HUMAN Apoptosis regulator BAX 21170.8 1 Cancer
Q13085 COA1_HUMAN Acetyl-CoA carboxylase 1 265382.7 1 Cancer Breast cancer
Q13153 PAK1_HUMAN Serine/threonine-protein kinase PAK 1 60608.8 4 Cancer
Q14653 IRF3_HUMAN Interferon regulatory factor 3 47189.7 2 Cancer
Q15796 SMAD2_HUMAN Mothers against decapentaplegic homolog 2 52272.8 1 Cancer
Q5JWF2 GNAS1_HUMAN Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas 110955.6 67 Cancer Breast cancer
Q7LG56 RIR2B_HUMAN Ribonucleoside-diphosphate reductase subunit M2 B 40710.5 5 Cancer
Q8WUF5 IASPP_HUMAN RelA-associated inhibitor 89036 15 Cancer
Q92466 DDB2_HUMAN DNA damage-binding protein 2 47833.4 5 Cancer
Q96RG5 Q96RG5_HUMAN Insulin receptor substrate 2 insertion mutant 137347.9 1 Cancer Breast cancer
P31947 1433S_HUMAN 14-3-3 protein sigma 27756.7 67
P62993 GRB2_HUMAN Growth factor receptor-bound protein 2 25190.4 32
P46108 CRK_HUMAN Proto-oncogene C-crk 33810 18
Q16539 MK14_HUMAN Mitogen-activated protein kinase 14 41267.1 2
P42224 STAT1_HUMAN Signal transducer and activator of transcription 1-alpha/be 87279.6 62
Q13547 HDAC1_HUMAN Histone deacetylase 1 55067.8 120
Q92769 HDAC2_HUMAN Histone deacetylase 2 55328.8 31
P56545 CTBP2_HUMAN C-terminal-binding protein 2 48914.2 26
Q13363 CTBP1_HUMAN C-terminal-binding protein 1 47505.6 8
Q92793 CBP_HUMAN CREB-binding protein 265180.1 2
Q13616 CUL1_HUMAN Cullin-1 89622 12
P62136 PP1A_HUMAN Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 37487.8 179
P62140 PP1B_HUMAN Serine/threonine-protein phosphatase PP1-beta catalytic subunit 37162.6 9
P06493 CDC2_HUMAN Cell division control protein 2 homolog 34073.9 20
P61586 RHOA_HUMAN Transforming protein RhoA precursor 21754.1 12
P08134 RHOC_HUMAN Rho-related GTP-binding protein RhoC precursor 21992.3 4
Oxidative processes/redox
P00441 SODC_HUMAN Superoxide dismutase [Cu-Zn] 15925.9 35 Cancer Breast cancer
P03891 NU2M_HUMAN NADH-ubiquinone oxidoreductase chain 2 38934.8 4 Cancer Breast cancer
P04040 CATA_HUMAN Catalase 59718.9 3 Cancer Breast cancer
P04179 SODM_HUMAN Superoxide dismutase [Mn], mitochondrial precursor 24706.6 1 Cancer Breast cancer
P10599 THIO_HUMAN Thioredoxin 11729.7 28 Cancer Breast cancer
P15559 NQO1_HUMAN NAD(P)H dehydrogenase [quinone] 1 30848 40 Cancer Breast cancer
P16435 NCPR_HUMAN NADPH–cytochrome P450 reductase 76641.4 22 Cancer Breast cancer
P21912 DHSB_HUMAN Succinate dehydrogenase [ubiquinone] iron-sulfur subunit 31608.9 5 Cancer
P47985 UCRI_HUMAN Cytochrome b-c1 complex subunit Rieske, mitochondrial precursor 29649.4 2 Cancer Breast cancer
Q99757 THIOM_HUMAN Thioredoxin, mitochondrial precursor 18371.6 1 Cancer Breast cancer
Q07973 CP24A_HUMAN Cytochrome P450 24A1, mitochondrial precursor 58837.6 15 Cancer Breast cancer
P30041 PRDX6_HUMAN Peroxiredoxin-6 25019.2 150
P30044 PRDX5_HUMAN Peroxiredoxin-5, mitochondrial precursor 22012.5 110
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Table 1 Biological categorization of MCF-7 proteins matched in the DAVID disease/cancer database (entries in italic are
not all cancer markers, but were included in the list due to their functional relevance to the marker proteins)
(Continued)
P30048 PRDX3_HUMAN Thioredoxin-dependent peroxide reductase, mitochondrial precursor 27675.2 48
P32119 PRDX2_HUMAN Peroxiredoxin-2 21878.2 102
Q06830 PRDX1_HUMAN Peroxiredoxin-1 22096.3 191
Various metabolic functions and DNA/RNA processing
O43708 MAAI_HUMAN Maleylacetoacetate isomerase 24166.7 4 Cancer Breast cancer
P00390 GSHR_HUMAN Glutathione reductase, mitochondrial precursor 56221 1 Cancer Breast cancer
P00492 HPRT_HUMAN Hypoxanthine-guanine phosphoribosyltransferase 24563.6 32 Cancer
P00558 PGK1_HUMAN Phosphoglycerate kinase 1 44586.2 466 Cancer
P07099 HYEP_HUMAN Epoxide hydrolase 1 52915 9 Cancer Breast cancer
P11172 PYR5_HUMAN Uridine 5'-monophosphate synthase 52188.7 11 Cancer
P11586 C1TC_HUMAN C-1-tetrahydrofolate synthase, cytoplasmic 101495.6 149 Cancer Breast cancer
P15531 NDKA_HUMAN Nucleoside diphosphate kinase A 17137.7 154 Cancer Breast cancer
P21266 GSTM3_HUMAN Glutathione S-transferase Mu 3 26542.2 59 Cancer Breast cancer
P21964 COMT_HUMAN Catechol O-methyltransferase 30017.6 35 Cancer Breast cancer
P23921 RIR1_HUMAN Ribonucleoside-diphosphate reductase large subunit 90012.5 4 Cancer Breast cancer
P30876 RPB2_HUMAN DNA-directed RNA polymerase II subunit RPB2 133810.7 2 Cancer
P34896 GLYC_HUMAN Serine hydroxymethyltransferase, cytosolic 53049.1 23 Cancer Breast cancer
P35520 CBS_HUMAN Cystathionine beta-synthase 60548.3 9 Cancer Breast cancer
P61604 CH10_HUMAN 10 kDa heat shock protein, mitochondrial 10924.9 58 Cancer
P78417 GSTO1_HUMAN Glutathione transferase omega-1 27548 16 Cancer Breast cancer
Q07973 CP24A_HUMAN Cytochrome P450 24A1, mitochondrial precursor 58837.6 15 Cancer Breast cancer
Q13085 COA1_HUMAN Acetyl-CoA carboxylase 1 265382.7 1 Cancer Breast cancer
Q7LG56 RIR2B_HUMAN Ribonucleoside-diphosphate reductase subunit M2 B 40710.5 5 Cancer
Q7Z5J4 RAI1_HUMAN Retinoic acid-induced protein 1 203223.9 11 Cancer
Q92820 GGH_HUMAN Gamma-glutamyl hydrolase precursor 35941.2 17 Cancer
Q9UBB5 MBD2_HUMAN Methyl-CpG-binding domain protein 2 43228 7 Cancer Breast cancer
Q9UHN1 DPOG2_HUMAN DNA polymerase subunit gamma-2, mitochondrial precursor 54876.3 7 Cancer
Cytoskeleton organization
P07437 TBB5_HUMAN Tubulin beta chain 49639 230 Cancer Breast cancer
P62328 TYB4_HUMAN Thymosin beta-4 5049.5 15 Cancer
Q13509 TBB3_HUMAN Tubulin beta-3 chain 50400.3 127 Cancer Breast cancer
Q14980 NUMA1_HUMAN Nuclear mitotic apparatus protein 1 238113.2 505 Cancer Breast cancer
Q92747 ARC1A_HUMAN Actin-related protein 2/3 complex subunit 1A 41542.7 1 Cancer
Transport/trafficking
O14908 GIPC1_HUMAN PDZ domain-containing protein GIPC1 36026.7 34 Cancer Breast cancer
O75915 PRAF3_HUMAN PRA1 family protein 3 21600.4 19 Cancer
Q8N1B4 VPS52_HUMAN Vacuolar protein sorting-associated protein 52 homolog 82169.8 14 Cancer
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gression under p53 regulation. It modulates the activity of
signaling proteins by binding to phospho-Ser/Thr motifs,
and was found to be down-regulated in cancer cells. Pro-
hibitin, on the other hand, inhibits DNA synthesis, and isbelieved to be a negative regulator of cell proliferation.
Other players of the DNA replication machinery such as
the origin replication complex (ORC) subunits 3, 4 and 5,
the mini-chromosome maintenance (Mcm) proteins 2, 4
and 7, the replication protein A3 (RPA3 of RFA3) and flap
31
2
Figure 4 STRING functional association network of 153 G1-stage cancer markers: (1) maintenance of genome integrity/DNA repair;
(2) signaling/cell cycle regulation; (3) energy production/metabolism/stress/oxidative phosphorylation.
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http://www.biomedcentral.com/1471-2407/14/710endonuclease 1 (FEN1), as well as key proteins of the pro-
teasomal degradation pathway, were detected. Protein
degradation by the 26S proteasome pathway is an essential
cell cycle regulatory process as it acts as a one-way switchthat guarantees correct cell cycle phase transitions [20].
CUL1, a member of the Skp/Cullin/F-box complex (SCF)
that controls the levels of CDK inhibitors p21 and p27,
was also identified in the data set. Altogether, the data
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cycle machinery are identifiable by MS in G1-arrested
cells, and that these regulators act in various stages of pro-
tein synthesis and degradation, or protein alteration by
posttranslational modifications.Apoptosis
Apoptosis is a tightly regulated process of cell destruc-
tion which cancer cells evade in a variety of ways, and
this resistance has been recognized as a hallmark of
tumorigenesis [16,21]. The extrinsic pathway involves
the activation of transmembrane death receptors from
the tumor necrosis factor (TNF) superfamily (e.g., FAS
and TNF-α) by death signals/ligands from the cell
surface. Ligand binding results in the recruitment of
FAS-associated death domain protein FADD which as-
sociates with procaspase-8 causing its activation and
entry into the execution phase. The intrinsic pathway is
triggered by a variety of stimuli such as growth factor
withdrawal, hypoxia and direct DNA damage, among
other factors, and acts through the p53 stress sensor.
Once phosphorylated by DNA checkpoint proteins
(ATM and CHK2), MDM2 mediated ubiquitination and
tagging for proteolysis is impeded, and p53 proceeds to
the activation of pro-apoptotic BCL-2 and repression of
anti-apoptotic BCL-2 family of proteins. Increased p53
levels also lead to the increase of reactive oxygen spe-
cies (ROS) that cause mitochondrial damage and re-
lease of DIABLO, ARTS and HTRA2 that activate the
mitochondrial caspase cascade. The most relevant
apoptosis protein markers that were identified included
BAX (BCL-2 associated X protein which accelerates
programmed cell death by binding to- and antagonizing
apoptosis repressor BCL-2), AIFM1 (apoptosis-indu-
cing factor 1), PDCD5/6/7 (with roles in induction and/
or acceleration of apoptosis), DIDO1 (a programmed
cell death protein), CCAR1 (a cell cycle and apoptosis
regulator), ASC (a caspase-mediated apoptotic factor),
HTRA2 (an inhibitor of the activity of inhibitors of
apoptosis proteins), BID (BH3-interacting domain
death agonist, a pro-apoptotic protein from the BCL-2
family), PAWR (a down-regulator of anti-apoptotic
BCL-2), PAK1 (with roles in protection against apop-
tosis), API5 (an apoptosis inhibitor), and members of
the m-TOR signaling pathway proteins with roles in
cell survival and evasion of apoptosis [15,21]. Beyond
apoptosis, the activities of these proteins have broad
ramifications into a multitude of signaling pathways
including MAPK, ErbB and p53. BAX and PAK1 repre-
sent not only the most interconnected pro- and anti-
apoptotic markers, but also provide a link between the
DNA damage repair, proliferation and signaling protein
clusters (see Figure 4).DNA damage response
Cells have developed various DNA repair mechanisms to
correct for genomic damage caused by replication errors,
chemical or environmental factors. The DNA damage
repair proteins that were identified in G1 represent a
large cluster of interacting proteins in Figure 4, and
match the entire range of DNA damage response
(DDR) pathways including mismatch repair (MSH),
base excision repair (XRCC), nucleotide excision repair
(XPC, PNKP, ERCC2), single and double strand break
repair (XRCC, TP53BP, RAD50, PARP, PCNA, APEX,
LIG3, PRKDC), homologous recombination and non-
homologous endjoining [22]. A manifold of connections
among all DNA repair proteins highlights the complex
set of mechanisms that were developed by cells to pre-
serve the genome integrity. Proteins with multiple in-
teractions and roles such as PARP1 and PCNA are at
the center of the DNA damage response network, and,
as noted earlier for the apoptotic proteins, provide the
functional link between the DNA damage, proliferation
and cell cycle signaling clusters. As PARP1 has been
found to be involved in the initiation of ssDNA break
repair, and to play a major role in tumor development
when dsDNA break repair cannot proceed via BRCA1/
BRCA2 mediated homologus recombination due to
various BRCA1/BRCA2 deficiencies, a variety of PARP
inhibitors are under development for treating not just
cancer, but also stroke and cardiovascular diseases [15].
Angiogenesis
Angiogenesis is the highly regulated process of new
blood vessel formation for the purpose of nutrient and
oxygen supply required for cell function and survival
[16]. Angiogenesis is a hallmark of cancer, but can be
tied to other processes in the cell such as inflammation
and wound healing [23]. G1-proteins with roles in
angiogenesis included the gene products of MAPK14
(mitogen activated protein kinase), AAMP (angio-
associated migratory cell protein), VEZF1 (vascular
endothelial zinc finger), RNH1 (RINI) (ribonuclease/
angiogenin inhibitor), STAT3 and p300/CBP (CREB-
binding protein) [15]. MAPK14 can be activated by
proinflammatory cytokines and through its kinase ac-
tivity has roles in cell cycle regulation. AAMP has
additional roles in cell migration and VEZF1 in tran-
scription regulation and cellular defense response.
RNH1 is an angiogenin inhibitor, STAT3 an angiogen-
esis modulator, while the p300/CBP proteins act as
transcriptional co-activators of the angiogenic factor
VEGF (vascular endothelial growth factor) [15,16,23].
Both pro- and anti-angiogenic factors possess various
additional biological functions. MAPK14 and STAT3
lie at the heart of multiple signaling pathways that me-
diate gene expression in response to various stimuli,
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angiogenesis to cell growth, proliferation and apoptosis.Cell adhesion, migration, tissue invasion
Cell adhesion and migration play important roles in
the initiation of tumor invasion and metastasis [24,25].
Several tight junction (TJ) proteins, among which ZO1
and ZO2, and numerous adherens junction (AJ) pro-
teins, which included α- and δ-catenin, were identified.
Tight junctions (TJ) regulate the passage of ions and
solutes between cells, while adherens junctions (AJ)
participate in the initiation and stabilization of cell-cell
contacts. Much broader roles in signal transduction,
gene expression, cell cycle modulation and cytoskel-
eton regulation have been, however, described for these
proteins. Transmembrane E-cadherin proteins use
their extracellular domain to interact with E-cadherins
on adjacent cells, and their intracellular domain to interact
with p120-catenin (δ-catenin/CTND), α-catenin (CTNA)
and β-catenin (CTNB). The catenins provide a link to the
actin cytoskeleton and signaling pathways. Reduced levels
of CTNA have been implicated in epithelial cancers, in-
cluding breast cancer, and have been associated with in-
creased invasiveness. CTND plays a role in the regulation
of cell motility by interaction with RHO GTPases, and it
has been implicated in breast cancer progression. On the
cell surface, MUC1 (mucin), a membrane-bound O-
glycosylated protein, plays additional roles in cell adhesion
(the α-subunit) and the modulation of intracellular signal-
ing pathways (the β-subunit) that include ERK, SRC,
NF-kappa-B, RAS/MAPK and p53. Changes in the glyco-
sylation pattern or overexpression of this protein have
been frequently associated with carcinomas [26].
Cell motility involves cytoskeleton reorganization to
extend the cell into the intended direction, as well as
sever and create cell adhesions at the trailing and leading
edges, respectively [27]. RHO, RAC and CDC42 are well
studied cell motility regulators that belong to the RHO
subfamily of RAS superfamily of GTPases [6]. Overex-
pression of these proteins has been linked to progression
and metastasis of breast cancer. In addition, CATD, an
estrogen regulated aspartyl protease that cleaves sub-
strates such as fibronectin and laminin, has been associ-
ated with cell invasion and tumor invasiveness in breast
cancer. TYB4 (with roles in actin polymerization),
PTN11 (a protein tyrosine phosphatase involved in sig-
naling) and LEG3 (carbohydrate binding) play additional
roles in cell adhesion, migration and proliferation, while
the expression of the MTA1 protein was correlated with
metastatic potential [28]. PAK1, a Ser/Thr p21-activating
kinase, is part of a family of proteins that link RHO
GTPases to cytoskeleton reorganization and nuclear sig-
naling, serving as targets for the small GTP bindingproteins CDC42 and RAC [15]. It is known to regulate
cell motility and morphology.
Differentiation
Cell differentiation, proliferation and cell cycle regula-
tion are processes that work concurrently, but independ-
ently, sharing certain key players with individual
regulatory function [29]. Differentiation is the process by
which unspecialized cells reach a terminal, non-
proliferative state by acquiring structural and functional
characteristics to perform a specific function [6]. Block-
ing of differentiation plays an important role in cancer
pathogenesis, as poor cell differentiation correlates to
more aggressive tumor phenotypes, and viceversa. There
is evidence suggesting that the mechanisms that prevent
hyperphosphorylation of RB favor differentiation, while
mechanisms that promote RB hyperphosphorylation
favor a block in differentiation [6]. Complementing the
cell cycle and cell proliferation regulators (RB, MAPK,
RAS-related proteins and protein phosphatases), a series
of proteins with various roles in differentiation have
been identified: GATA3, PPARG, EDF1, NME1 or
NDKA, LGALS1 or LEG1, LGALS3, CTNNA1, GDAP1
and ROD1 [15]. GATA3, a transcriptional activator in-
volved in the differentiation of luminal epithelial cells
such as MCF-7 and that has been suggested as a breast
cancer predictor, displays an inverse correlation to me-
tastasis capability and strong association with estrogen
receptors, though it does not appear to be involved in
the estradiol signaling pathway [30]. In addition, GATA3
represses adipocyte differentiation by suppressing the
peroxisome proliferator-activated receptor γ (PPARG).
On the other hand, EDF1 (endothelial differentiation-
related factor), a transcriptional activator, stimulates
PPARG activities. The NME1, LGALS, CTNNA1 (ca-
tenin, alpha1), GDAP1 and ROD1 proteins have roles in
inducing or blocking cell differentiation. The overlap-
ping functional relationships between differentiation, in-
vasive properties, angiogenesis and proliferation are
clearly observable in Figure 4, and point in the direction
of the same signaling proteins, strengthening the rele-
vance of this protein set to determining cell fate.
Oxidative phosphorylation/stress//redox regulation
Oxidative phosphorylation is an energy-producing meta-
bolic pathway composed of five mitochondrial membrane-
bound multiprotein complexes (I-V) which use the energy
generated by electron transfer to synthesize ATP [31,32].
A number of proteins belonging to NADH dehydrogenase,
NADH ubiquinone oxidoreductase and ATP synthase
complexes, cytochrome b-c complexes/oxidases, peroxire-
doxins and thioredoxins, were identified. Aberrancies in
oxidative phosphorylation such as electron leakage leading
to oxidative stress, and mutations in these complexes,
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(ROS) formed from leaked electrons play a role in DNA
damage and apoptosis, inducing oxidative stress, which in
turn can promote angiogenesis and metastasis. Peroxire-
doxins and antioxidant enzymes, such as [Cu-Zn] super-
oxide dismutase (SODC or SOD1, and SODM or SOD2)
and catalase (CATA) modulate the levels of ROS and are
important players in the cellular detoxification processes.
While overproduction of ROS induces cell death, moder-
ate levels reportedly can confer resistance to apoptosis
and promote cell proliferation. Over expression of SOD1
and CATA has been reported in breast tumors and other
types of cancer. APEX1, with roles in cell detoxification
and the redox regulation of transcriptional factors, also
displays activities in the base excision repair of DNA le-
sions induced by oxidative and alkylating agents where it
functions as an apurinic/apyrimidinic endodeoxyribonu-
clease [15]. While this group of proteins formed a rather
independent cluster of interacting partners in Figure 4
(see cluster 3), the link to the signaling and DNA damage
response clusters is clearly evidenced through the super-
oxide radical capturing SOD1 and SOD2 proteins.Table 2 Signaling pathways and associated proteins
Pathway
MAPK: Proliferation, differentiation, migration
ErbB: Proliferation, differentiation, survival, angiogenesis and adhesion/
motility/migration/invasion
Cell cycle: Proliferation
DNA damage repair: Maintenance of genome integrity
Apoptosis: Cell death
p53: Cell cycle arrest, apoptosis, senescence, inhibition of angiogenesis/
metastasis, inhibition of IGF-1/mTOR pathway
TGF-β: proliferation, apoptosis, differentiation, migration
NF-kappa-B: Regulation of genes involved in immunity, inflammation,
cell survival
Wnt: Cell division, development, adhesion
Jak/STAT: Growth, proliferation, development, cell fate, immunity,
cell cycle, apoptosis
Toll-like: Innate immune responses to pathogenic bacteria
Notch: Proliferative signaling, angiogenesis
VEGF: Angiogenesis
Adhesion/integrin signaling: Cell migration, tissue invasion
Ca signaling: Proliferation, apoptosis, metabolism
Insulin signaling: Maintenance of energy metabolism/homeostasis
Chemokine: Immune response, cell growth, differentiation, survival,
migration, apoptosis, regulation of cytoskeleton
PPAR signaling: Lipid metabolism, adipocyte differentiation
Fatty acid biosynthesisSignaling
The largest sub-set of cancer markers included 48 pro-
teins with various roles in modulating a broad range of
signal transduction events (Table 2). Numerous path-
ways that promote cell proliferation are activated by the
binding of various ligands to cell surface receptor tyro-
sine kinases (RTKs). SH2-containing proteins such as
GRB2, SHC, STAT3 which bind phosphorylated RTKs,
were present in the cytoplasmic fractions. GRB2, SHC1
and CRK are known as adaptor proteins because of their
specific role as intermediates in protein-protein interac-
tions [6,16]. When GRB2 binds a phosphorylated RTK
directly or through SHC1, it can initiate a signaling cas-
cade by successive binding of SOS, a guanine nucleotide
exchange factor that activates the membrane bound
RAS protein by replacing GDP with GTP. Out of four
existing mammalian RAS proteins, H-RAS was identified
in the cytoplasmic fractions. RAS has a vast list of ef-
fector proteins which can activate different signaling
pathways, of which the major ones are RAL-GDS, RAC/
RHO, RAF, PI3K and RAL-GEF. The RAF mitogenic path-
way has been described as possibly the most relevant toRepresentative proteins
HRAS/RASH, HSP71, HSP7C, HS71L, NF-kappa-β or TF65/RELA, GNAS,
PAK1, RAC1, SHC1, MAPK14, GRB2, CRK
SHC1, PAK1, GRB2, CRK, HRAS
SMAD2, SHC1, 1433s/SFNC/stratifin, HDAC1/2, CREBBP, CUL1, CDC2
PARP1, TP53BP, PCNA, PRKDC, DDB2, CREBBP (Table 1)
BCLF1, BAX, TF65, IASPP
BAX, RIR2B, DDB2, CDC2, 1433s
SMAD2, CREBBP, CUL1, RHOA
NF-kappa-β/TF65/RELA
CTNB1, SMAD2, CTBP2, CREBBP, CUL1, RAC1
STAT 3, PTN11, STAT1, GRB2, CREBBP
TLR2, IRF3, TF65, MAPK14, STAT1, RAC1
HDAC1, CTBP1/2, CREBBP
MAPK14, SHC1, RAC1, HRAS
CTNB1, PAK1, GRB2, CRK, HRAS, RAC1, PP1A/B, CDC2, RHOA, ILK,
MUC1, PTN11
AT2A2, GNAS1
Q96RG5, TFR1, PTN11, COA1, SHC1, GRB2, CRK, PP1A/B










































Figure 5 STRING functional association network of central cancer
markers that link the DNA repair, signaling and metabolic clusters.
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http://www.biomedcentral.com/1471-2407/14/710cancer pathogenesis due to its capability to activate several
growth-promoting genes, provide anchorage independ-
ence, repress contact inhibition, change cell shape and in
general promote proliferation [6,16]. Downstream proteins
in this pathway include the extracellular regulated protein
kinases (ERK) ERK1 and ERK2. Pertinent to the G1/S
transition, activation of ERK1 and ERK2 is required up to
late G1 for expression of cyclin D1 and successful S entry,
though the activity of these proteins is not necessary after
the R-point. Further implications of RAS activation in-
volve sustained angiogenesis and evasion of apoptosis.
Overall, the deregulation of the SOS-RAS-RAF-MAPK
signaling cascade is heavily implicated in acquired growth
factor autonomy. In the larger landscape, RTK initiated
signaling integrates ErbB, Jak/STAT, integrin, insulin, cell
cycle/DNA repair and apoptosis signaling, chemokine sig-
naling integrates Jak/STAT, G-protein and Ca signaling
pathways, while Ras, downstream in the cell, further mod-
ulates the outcome of TGF-β, Wnt and NF-kB signaling.
The ultimate result is a complex orchestration of cross-
talk and positive/negative feed-back loops that control cell
cycle progression.
Discussion
A first important finding of this study reveals that the
majority of cancer marker proteins that were compiled
in the DAVID disease database from rather random and
unrelated studies on cancer, and that were identified in
MCF-7 G1 cells, are not isolated players in the develop-
ment of the disease, but part of multiple regulatory net-
works that integrate seamlessly with the hallmarks of
cancer. A close examination of Figure 4 reveals that the
proteins displaying the largest number of interactions
(>10-15) also represent the functional links between the
three major clusters: SOD1, SOD2 and CAT (from the
oxidative stress cluster), PARP1, PCNA and APEX1
(from the DNA damage cluster) and STAT3, RAC1,
RELA and ILK (from the signaling cluster). A STRING
interaction diagram of this circle of proteins and of a
few additional regulatory proteins with >5 interactors
highlights in detail these central functional relationships
(Figure 5). The outcome is conclusive: DNA damage co-
exists with oxidative phosphorylation and stress, and, in
response, multiple signaling pathways work in tandem to
determine the fate of the cell. Cancer marker signaling
proteins such as STAT3, RAC1, RELA and ILK are in-
volved through their parent pathways essentially in all
aspects of signal transduction (Table 2: Jak/STAT, NF-
kappa-β, MAPK, Wnt, Toll-like, VEGF, chemokine, in-
tegrin), linking a vast array of extracellular stimuli to the
intracellular signaling cascades that govern cell prolifera-
tion, repair, differentiation, immune response, invasion,
metastasis or death. SOD2, SOD1 and CATA are key
antioxidant defense enzymes that alleviate the toxiceffects of hydrogen peroxide and superoxide anions/rad-
icals produced as a result of various metabolic processes,
while PARP1 and PCNA orchestrate DNA replication
and damage repair functions to ensure healthy cell pro-
liferation. Alterations in the activity of these genes and
their protein products associate inherently, therefore,
with the development of cancerous cell states. While
members of all three major clusters were represented in
both the nuclear and cytoplasmic cellular subfractions,
the DNA damage repair components prevailed in the
nuclear fraction, while the signaling and cellular detoxifi-
cation components in the cytoplasm. Based on their
functional roles, the nuclear markers and some of the
signaling proteins are indicative of a network of drug
targets, while the cytoplasmic proteins of a network or
putative biomarkers, respectively. In recent years, the
value of such a network-based set of markers has been
recognized [33,34]. New concepts such as network bio-
markers and dynamical network biomarkers have gained
popularity, primarily due to the promises brought to im-
proving early diagnostics, sensitivity and specificity, and
to behaving more robustly with smaller number of sam-
ples [33]. Moreover, the study of network models has
suggested that therapies aimed at the inhibition of a
number of drug targets, even if small and even if partial,
can be much more effective than therapies aimed at the
complete inhibition of a single target [34].
The second finding of this study reveals that a com-
mon thread of the identified cancer marker clusters is
the presence of both agonist and antagonist members
within the cluster. The results confirm that entire signal-
ing pathways may have both proliferative and inhibitory
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STAT3 results in opposite effects on tumorigenesis.
While STAT3 is considered an oncogene that promotes
cell survival/proliferation, motility and immune toler-
ance, STAT1 is a tumor suppressor through its anti-
proliferative, pro-apoptotic and angiogenesis-inhibitor
activities [23]. The active TGF-β signaling pathway has,
on the other hand, a role in growth inhibition. Upon ac-
tivation of the pathway, SMAD2 and SMAD3 undergo
phosphorylation in the cytosol followed by binding of ei-
ther phosphorylated protein to SMAD4, nuclear trans-
location of the complex, and transcription factor activity.
Relevant to cell cycle control, the CDK inhibitors p15
and p21 are the important targets of this pathway [6].
Repression of TGF-β signaling is therefore a way in
which cancer cells can achieve insensitivity to anti-
growth signals. For example, EVI1 and AML1/EVI1 in-
hibit the transcription factor activity of SMAD3 in the
nucleus by direct interaction through a zinc-finger motif.
Furthermore, CTBP (C-terminal binding protein), a
transcriptional repressor necessary for the inhibition of
SMAD3 by EVI1, recruits a histone deacetylase (HDAC)
complex which aids in the repression of antigrowth sig-
nals [24]. The two CTBP vertebrate homologues
(CTBP1 and CTBP2), as well as the histone deacetylases
HDAC1 and HDAC2, were identified in the nuclear frac-
tions, suggesting that important participants of acquisi-
tion of insensitivity to antigrowth signals are in place in
MCF-7 cells. For a complex disease such as cancer, that
hosts entirely deregulated but viable signaling pathways,
the identification of a novel regulatory network such as
suggested by Figures 4 and 5, of its components and of its
dynamic behavior, is expected to have a major impact on
clarifying the mechanistic details of disease progression.
The third finding of the study reveals that the identi-
fied signaling clusters control or modulate not one, but
several cancer-related biological processes. Likewise,
physiological responses within a cell are elicited not
through one, but through multiple signaling pathways.
The MAPK and Jak/STAT pathways have ramifications
within, virtually, all biological processes that determine
the fate of a cell. The delineation of a panel of proteins
that modulate cell adhesion/motility/metastasis (CTNB1,
MUC1, PAK1, RAC1, RHOA, PTN11, CRK, GRB2,
PP1A/B), while simultaneously playing central roles in
signaling pathways such as MAPK, ErbB, IGF and Jak/
STAT (and, as a result, in all aspects of cell division,
proliferation, apoptosis and differentiation, see Tables 1
and 2), is vital to providing insights into the mechanism
used by cancer cells to invade adjacent tissues and into
the correlation of these processes with events occurring
within the cytoplasmic signal-transduction pathways.
Simultaneously, the placement of both pro- and anti-
apoptotic proteins within a broader panorama of cellcycle regulation, survival, proliferation and differenti-
ation proteins is critical to exploring the impact of anti-
apoptotic factor up-regulation or pro-apoptotic factor
down-regulation in cancer. Such perspectives can reveal
clues into whether cancer cells have (or not) the ability
to activate self-destruction signaling mechanisms, and
into the strategies evolved by cancer cells to evade apop-
tosis and respond to cellular signals that indicate a malfunc-
tion of the cell proliferation machinery or the presence of
physiological stress. Future protein differential expression
studies will be able to validate which networks prevail in
the case of particular pathological cancer phenotypes.Conclusions
In this work, through proteomic profiling of the G1
stage of MCF-7 cells, and by making use of publically
available information and bioinformatics tools, we un-
covered a highly interconnected network of nuclear and
cytoplasmic cancer markers with regulatory role in bio-
logical processes representative of all hallmarks of cancer.
Protein interaction analysis and biological characterization
of the data revealed that clusters pertaining to cell cycle
regulation, signaling, DNA repair, differentiation, angio-
genesis and apoptosis, were particularly well represented
in the pool of identified proteins. The three major net-
works formed by these cancer markers, i.e., signaling,
maintenance of genome integrity and oxidative stress, are
indicative of the different mechanisms that cancer cells
utilize to maintain viability in the absence of mitogenic
stimulation and to possibly evade the R-restriction point
and sustain an aberrant proliferative status. Due to their
collective and intertwined roles on the proliferative behav-
ior of cancer cells, the identified markers represent a panel
of broad functional relevance to both biomarker and drug
discovery research. The combined biomarker/drug-target
potential is elevated by the fact that the panel emerged
from a list of markers representative of a number of can-
cerous cell states, compiled rather randomly by on-line
bioinformatics tools. The data suggest that proteins with
redundant or multiple roles in the control of a cell’s fate
represent the most informative cancer markers and the
most valuable leads for the development of multiplexed
biomarker assays and of anti-cancer drugs with increased
therapeutic potential.Additional files
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